In a phase 1b/2 clinical study, the combination therapy of APR-246 and azacitidine produced a 71% overall response rate, including a 41% CR rate, in patients with TP53-mutated high-risk MDS or AML (Table 4) [91]. The gene discussed is TP53; the disease is myelodysplastic syndrome.